Results 181 to 190 of about 776,039 (330)

Challenges & Insight into New Drug Approval

, 2001
Margot J. Fromer
openalex   +1 more source

Assessing the Impacts of the Prescription Drug User Fee Acts (PDUFA) on the FDA Approval Process [PDF]

, 2005
Ernst R. Berndt, Adrian H. B. Gottschalk, Tomas Philipson, Matthew W. Strobeck   +3 more
openalex   +1 more source

Beyond digital twins: the role of foundation models in enhancing the interpretability of multiomics modalities in precision medicine

FEBS Open Bio, EarlyView.
This review highlights how foundation models enhance predictive healthcare by integrating advanced digital twin modeling with multiomics and biomedical data. This approach supports disease management, risk assessment, and personalized medicine, with the goal of optimizing health outcomes through adaptive, interpretable digital simulations, accessible ...
Sakhaa Alsaedi, Xin Gao, Takashi Gojobori   +2 more
wiley   +1 more source

US drug companies will meet more than half the cost of drug approval

, 2002
D. Josefson
openalex   +2 more sources

Drug approval system questioned in US and Canada [PDF]

, 2005
Laura Eggertson
openalex   +1 more source

Acacetin reduces endoplasmic reticulum stress through the P‐eNOS/PERK signaling pathway to attenuate MGO‐induced vascular endothelial cell dysfunction

FEBS Open Bio, EarlyView.
We investigated a potential protective effect of acacetin, a naturally occurring flavonoid, against methylglyoxal (MGO)‐induced endothelial dysfunction in human umbilical vein endothelial cells and its mechanism of action. Acacetin can could inhibit MGO‐induced intracellular calcium ion influx, enhance the expression levels of phosphorylated ...
Zhen Zhang, Kaien Hu, Zhaohui Fang, Sihai Wang, Jie Chen, Dengke Yin, Caiyun Zhang, Gefei Ma   +7 more
wiley   +1 more source

Evolving Landscape of New Drug Approval in Japan and Lags from International Birth Dates: Retrospective Regulatory Analysis. [PDF]

Clin Pharmacol Ther, 2021
Tanaka M, Idei M, Sakaguchi H, Kato R, Sato D, Sawanobori K, Kawarasaki S, Hata T, Yoshizaki A, Nakamura M, Ikuma M.   +10 more
europepmc   +1 more source

A Proposal for Radical Changes in the Drug-Approval Process [PDF]

, 2006
Alex Philchenkov
openalex   +1 more source

Red blood cells could protect miRNAs from degradation or loss thanks to Argonaute 2 binding

FEBS Open Bio, EarlyView.
The present work investigates the presence and the stability of miRNAs into RBCs, both native and engineered. The observed stability is due to the Ago2 bound resulting in minimal RISC. Indeed, if the miRNA‐Ago2 complex is present, miRNAs are protected from release or degradation and they are biologically active. Thus, RBCs can act as miRNA carriers for
Elena Perla, Faiza Abbas, Luigia Rossi, Mauro Magnani, Sara Biagiotti   +4 more
wiley   +1 more source

Are Quality of Randomized Clinical Trials and ESMO-Magnitude of Clinical Benefit Scale Two Sides of the Same Coin, to Grade Recommendations for Drug Approval? [PDF]

J Clin Med, 2021
Rodriguez A, Esposito F, Oliveres H, Torres F, Maurel J.   +4 more
europepmc   +1 more source